CSL Biotherapies Announces Start of U.S. H1N1 Vaccine Clinical Trials
Published: Aug 24, 2009
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--CSL Biotherapies has announced the initiation of the company’s first U.S. clinical trials of its candidate Influenza A/H1N1 2009 vaccine. Study investigators will administer vaccinations to the first U.S. study volunteers today, August 24. The studies will determine the safety of CSL’s candidate vaccine and its ability to elicit an immune response (also referred to as immunogenicity) in adults and children. The pediatric study will evaluate CSL’s candidate vaccine in a thimerosal-free (i.e., preservative-free) formulation.